98%
921
2 minutes
20
Background: Morquio syndrome is an autosomal recessive deficiency of -acetylgalactosamine-6-sulphate, causing an accumulation of glycosaminoglycans that leads to musculoskeletal and cardiopulmonary abnormalities. We describe the management of aortic stenosis via a transcatheter aortic valve implantation (TAVI) in a patient with Morquio syndrome.
Case Summary: A 73-year-old woman with Morquio syndrome presented with one year of progressive dyspnoea and was found to have severe aortic stenosis on transthoracic echocardiogram. She previously underwent an attempted TAVI via transfemoral approach, which was aborted due to iliac artery dissection and occlusion. A multidisciplinary team opted for TAVI via a surgical femoral artery cut-down approach. She was last seen and recovering well three months post-procedure.
Discussion: Musculoskeletal and cardiopulmonary manifestations of Morquio syndrome place patients at higher risk for procedural complications. As medical techniques improve and patients survive later into adulthood, increasing numbers will require aortic valve replacements to improve quality of life. This case highlights the challenges of aortic valve disease management in patients with Morquio syndrome, and suggests that TAVI can be safely performed using a surgical femoral cut-down approach.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11945293 | PMC |
http://dx.doi.org/10.1093/ehjcr/ytaf117 | DOI Listing |
JAAD Case Rep
August 2025
Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Int J Mol Sci
July 2025
Nemours Children's Health, Wilmington, DE 19803, USA.
Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disorder causing systemic skeletal dysplasia due to a deficiency of N-acetyl-galactosamine-6-sulfate sulfatase (GALNS) enzyme activity, leading to the impaired degradation and accumulation of glycosaminoglycans (GAGs), keratan sulfate (KS) and chondroitin-6-sulfate. While treatments such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) are available, they have significant limitations regarding efficacy in skeletal tissues and long-term safety, highlighting the need for more effective therapies. We evaluated a novel gene therapy approach using a dual Integrase-deficient lentiviral vector (IDLV) to deliver an expression cassette that includes human cDNA and Cas9 sgRNA, targeting the upstream region of the mouse initial codon.
View Article and Find Full Text PDFMol Genet Metab Rep
September 2025
Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, UK.
Mucopolysaccharidoses are a heterogeneous group of rare lysosomal storage disorders (LSDs) caused by genetic mutations resulting in the deficiency of lysosomal enzymes responsible for the degradation of glycosaminoglycans (GAGs). The potential association of hematological abnormalities and clinical manifestations in MPS disorder highlights the importance of exploring the role of regular iron studies and hematological tests in at risk MPS patients as undiagnosed anemia has been shown to worsen clinical outcomes. In this study, therefore, we aimed to describe the hematological abnormalities and iron studies in adult patients with MPS disorders in the context of their therapies.
View Article and Find Full Text PDFJ Orthop Surg Res
July 2025
Spine Center, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai, 200092, China.
Study Design: Retrospective Study.
Objective: Type IVA mucopolysaccharidosis (MPS) is often associated with atlantoaxial deformity, and lacks a unified surgical treatment standard or classification system. We examined the value and clinical applicability of a new classification system for atlantoaxial deformities caused by type IVA MPS.
Surg Neurol Int
June 2025
Department of Spinal Neurosurgery, Kyoto Katsura Hospital, Kyoto, Japan.
Background: Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive lysosomal genetic storage disorder caused by the accumulation of glycosaminoglycans in tissues and organs. A 10-month-old male with MPS VI had originally undergone foramen magnum decompression (FMD)/C1 followed by lifelong enzyme replacement therapy (ERT). At age 15, the patient underwent successful surgical treatment for retro-odontoid disease and recurrent cranio-cervical junction (CCJ) stenosis through a C1-C3 laminectomy and expansive duroplasty.
View Article and Find Full Text PDF